Sutro Biopharma

Sutro Biopharma: Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has three wholly-owned ADCs that are on clinical pathways and three high value collaborations with BMS, Merck, and EMD Serono. FolRα-targeting ADC (STRO-002) Phase 1, anticipated preliminary data in ovarian cancer and EOP1/2 FDA meeting in 2H21. CD74-targeting ADC (STRO-001) Phase 1 dose-expansion to be initiated in 2H21. Pre-clinical data and IND projections for STRO-003 in general cancer anticipated for 2H21. BMS collaboration for CC-99712 (BCMA-targeting ADC) granted orphan drug designation in February 21. IND-enabling tox initiated for Merck collaboration on a cytokine derivative program.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Infectious Disease, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Address:
310 Utah Ave
Suite 150
South San Francisco, CA 94080
United States

Company Participants at Solebury Trout Virtual Management Access Event 2021

Bill Newell
Sutro Biopharma, Chief Executive Officer
Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio, Inc. Mr. Newell is also a Board member on BIO

Top 10 Holders of Sutro Biopharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Franklin Advisers, Inc. 6.13 2,828,579 56.23 13F 6/30/21
Eventide Asset Management LLC 5.14 2,370,975 47.13 13F 6/30/21
State Street Corp. 4.84 2,233,692 44.41 13F 6/30/21
First Light Asset Management LLC 4.50 2,072,875 41.21 13F 6/30/21
Vanguard Group, Inc. (Subfiler) 4.34 2,001,775 39.80 13F 6/30/21
The Vanguard Group, Inc. 4.20 1,934,581 38.46 Funds 7/31/21
BlackRock Fund Advisors 4.14 1,908,674 37.94 13F 6/30/21
SV Health Investors LLC 3.96 1,824,542 36.27 13F 6/30/21
Baillie Gifford & Co. 3.89 1,794,173 35.67 13F 6/30/21
Suvretta Capital Management LLC 3.72 1,715,381 34.10 13F 6/30/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.